Lower dosages of rituximab used successfully in the treatment of anti-NMDA receptor encephalitis without tumour

In patients with anti-NMDAR encephalitis who did not respond to first-line immunotherapy, early application of lower dosages of rituximab could efficiently reduce CD19+ B-cell counts of peripheral blood and improve the prognosis of anti-NMDAR encephalitis.